Prosecution Insights
Last updated: November 15, 2026
Application No. 18/360,947

POLISHING PAD FORMED FROM DUAL CURATIVE

Non-Final OA §103
Filed
Jul 28, 2023
Examiner
SERGENT, RABON A
Art Unit
1765
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Dupont Electronic Materials Holding Inc.
OA Round
3 (Non-Final)
55%
Grant Probability
Moderate
3-4
OA Rounds
79%
With Interview

Examiner Intelligence

Grants 55% of resolved cases
55%
Career Allowance Rate
557 granted / 1010 resolved
-9.9% vs TC avg
Strong +24% interview lift
Without
With
+24.0%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
36 currently pending
Career history
1058
Total Applications
across all art units

Office Action

§103
Detailed Office Action Notice of Pre-AIA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 2. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 22 September 2026 has been entered. Prior Art Rejection 3. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. 4. Claims 1 and 6-10 are rejected under 35 U.S.C. 103 as being unpatentable over Qian et al. (US 2015/0306731 A1) in view of Barton et al. (US 2022/0226959 A1, as evidenced by Hobbs et al. (US 2013/0071571 A1), and further in view of Weis et al. (US 2018/0071888 A1) and Gajewski (US 5,223,599). Qian et al. disclose a chemical mechanical polishing pad produced from an isocyanate terminated prepolymer, having an isocyanate content of 8.5 to 9.5 weight percent, and a curative blend comprising a polyol, corresponding to applicant’s high molecular weight polyol (b) (instant claim 1), and a difunctional compound, wherein 3,5-dimethylthio-2,4-toluenediamine and its isomers are disclosed (instant claim 1). See abstract and paragraphs [0011]-[0018], [0036], and [0037] within Qian et al. The disclosed curative components are used in amounts that overlap the claimed weight ratios of instant claim 1. See paragraphs [0014], [0026], and [0035] within Qian et al. Regarding instant claim 7, within paragraph [0040], the claimed active hydrogen group to isocyanate group ratio is disclosed. Regarding instant claim 8, the claimed density range is disclosed within paragraph [0042]. Regarding instant claim 9, microelements, corresponding to applicant’s claimed expanded polymeric microspheres, are disclosed within paragraph [0041]. Regarding instant claim 10, groove patterns, corresponding to those claimed, are disclosed within paragraphs [0028] and [0029]. 5. Regarding the claimed prepolymer isocyanate content of 8.3 to 9.8 weight percent (instant claim 6), though the primary reference encompasses the majority of this range, it does not teach the claimed endpoints. Still, the claimed range was known to be useful for the production of isocyanate prepolymer to be used in the production of chemical mechanical polishing pads. This position is supported by the teaching within the abstract and paragraph [0006] of Weis et al. Accordingly, given this teaching and the closeness of the respectively disclosed ranges within the references, the position is taken that it would have been obvious to use the broader isocyanate content range to produce the composition of the primary reference, so as to arrive at the instant invention. Regarding applicant’s claimed curative component (a) of instant claim 1, though the primary reference discloses 3,5-dimethylthio-2,4-toluenediamine and its isomers, the primary reference fails to disclose curative (a), as claimed. Still, the instantly claimed diamine curative was a known curing agent component for curing a prepolymer used to produce chemical mechanical polishing pads. This position is supported by the teachings within paragraph [0072] and Examples 2, 4, 5, 7, 9, 10, and 11 of Barton et al., wherein Ethacure 300 is used as a curing agent for polyisocyanate prepolymer compositions used to produce chemical mechanical polishing pads. Furthermore, as evidenced by paragraph [0793] of Hobbs et al., Ethacure 300 comprises 95-97% dimethylthiotoluene diamine and 2-3% monomethylthiotoluene diamine, which corresponds to instantly claimed curative (a). Since it has been held that it is prima facie obvious to use a known compound for its known function, the position is taken that it would have been obvious to use this disclosed diamine as the diamine curative component of the primary reference, so to arrive at the instant invention. Furthermore, given the disclosed preferred use of 3,5-dimethylthio-2,4-toluenediamine within the primary reference, one would have reasonably expected Ethacure 300, containing almost completely this preferred diamine, to function equivalently as a curative for the prepolymer of Qian et al. 6. Regarding the teachings within the primary reference with respect to the diamine curative, it is noted that 3,5-dimethylthio-2,4-toluenediamine and its isomers are taught as being more preferred, while MBOCA is taught as being most preferred. However, at the time of invention, MBOCA was suspected of being a carcinogen, and its use within polyurethanes as a curing agent was not desirable relative to other non-carcinogenic curatives. This position is supported by the teaching within column 1, lines 35-45 of Gajewski. Accordingly, in view of this disclosure, one of ordinary skill would have been motivated to use another curative, as opposed to MBOCA. 7. Applicant has argued (1) that applicant has demonstrated unexpected results, relative to the closest available prior art, and has therefore rebutted the prima facie case of obvious and (2) that there is a lack of motivation to combine the teachings of Qian et al. and Barton et al. However, these arguments are not found persuasive for the following reasons. Regarding argument (1), firstly, applicant’s disclosure of the prepolymer used within his examples lacks adequate disclosure/definition to establish that the comparative examples are representative of the primary reference, considered to constitute the closed prior art. Secondly, the relied upon examples, Examples 1, 3 and 4 (Example 2 being outside the scope of the claims), of the instant invention are not commensurate in scope with the claims in terms of component species or amounts to establish that the argued unexpected results hold for the full scope of the claims. Note: In re Greenfield, 571 F.2d 1185, 1189, 197 USPQ 227, 230 (CCPA1978). Thirdly, regarding applicant’s argument concerning the use of MBOCA within Qian et al., applicant’s attention is directed to the aforementioned teaching within Gajewski explaining why one would have been motivated to use other than MBOCA as the curing agent of Qian et al. Regarding argument (2), applicant’s argument that there is insufficient motivation to combine the teachings of Qian et al. and Barton et al. is not well taken. The primary reference discloses the preferred use of the main diamine component of Ethacure 300 as a curative for the prepolymer of Qian et al. and given the extreme similarity of the respective diamine curing agents, one would have expected them to function equivalently to cure the prepolymer of Qian et al. The disclosure within Qian et al. regarding the use of a diamine curative that corresponds so closely to that claimed and that of Barton et al. successfully rebuts applicant’s statement that one would have had no motivation or reasonable expectation of success in isolating Ethacure 300 from Barton et al. and employing it within Qian et al. Given these relied upon teachings, there is insufficient reasoning/disclosure of record to support applicant’s position. It is noted that Barton et al. has been relied upon solely to establish that the instantly claimed diamine curing agent was known at the time of invention. It is further noted that the instant claims in no way exclude the argued low molecular weight diols of Barton et al.; therefore, this argument is not commensurate with the instant claims. Applicant’s arguments having been addressed, the prior art rejection as modified has been maintained. Conclusion 8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Rabon A Sergent whose telephone number is (571)272-1079. The examiner can normally be reached on Monday through Friday from 9:00 AM until 5:00 PM, ET. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Heidi Riviere Kelley, can be reached at telephone number (571)270-1831. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from Patent Center. Status information for published applications may be obtained from Patent Center. Status information for unpublished applications is available through Patent Center to authorized users only. Should you have questions about access to the USPTO patent electronic filing system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). Examiner interviews are available via a variety of formats. See MPEP § 713.01. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) Form at https://www.uspto.gov/InterviewPractice. /RABON A SERGENT/Primary Examiner, Art Unit 1765
Read full office action

Prosecution Timeline

Jul 28, 2023
Application Filed
Oct 01, 2025
Non-Final Rejection mailed — §103
Feb 25, 2026
Response Filed
Jun 02, 2026
Final Rejection mailed — §103
Sep 22, 2026
Request for Continued Examination
Sep 25, 2026
Response after Non-Final Action
Sep 30, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790514
Flame-Retardant Adhesive Composition for Structural Wood Bonding
3y 2m to grant Granted Nov 10, 2026
Patent 12790431
METHODS FOR THE RAPID PRODUCTION OF BLOCKED PREPOLYMERS
2y 11m to grant Granted Nov 10, 2026
Patent 12781155
MIXED HYDROXYETHER COMPOUNDS, PROCESS FOR MAKING SUCH COMPOUNDS, AND THEIR USE
4y 0m to grant Granted Nov 03, 2026
Patent 12780957
PROCESS FOR REMOVING CHLORINE FROM A PLASTIC MIXTURE
3y 2m to grant Granted Nov 03, 2026
Patent 12780986
SCHIFF BASE INCORPORATED DOUBLE METAL CYANIDE CATALYST FOR THE PRODUCTION OF POLYETHER POLYOLS
3y 6m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
55%
Grant Probability
79%
With Interview (+24.0%)
High
PTA Risk
Based on 1010 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month